Literature DB >> 16414988

Activated MEK suppresses activation of PKR and enables efficient replication and in vivo oncolysis by Deltagamma(1)34.5 mutants of herpes simplex virus 1.

Kerrington D Smith1, James J Mezhir, Kai Bickenbach, Jula Veerapong, Jean Charron, Mitchell C Posner, Bernard Roizman, Ralph R Weichselbaum.   

Abstract

Herpes simplex virus mutants lacking the gamma(1)34.5 gene are not destructive to normal tissues but are potent cytolytic agents in human tumor cells in which the activation of double-stranded RNA-dependent protein kinase (PKR) is suppressed. Thus, replication of a Deltagamma(1)34.5 mutant (R3616) in 12 genetically defined cancer cell lines correlates with suppression of PKR but not with the genotype of RAS. Extensive analyses of two cell lines transduced with either dominant negative MEK (dnMEK) or constitutively active MEK (caMEK) indicated that in R3616 mutant-infected cells dnMEK enabled PKR activation and decreased virus yields, whereas caMEK suppressed PKR and enabled better viral replication and cell destruction in transduced cells in vitro or in mouse xenografts. The results indicate that activated MEK mediates the suppression of PKR and that the status of MEK predicts the ability of Deltagamma(1)34.5 mutant viruses to replicate in and destroy tumor cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16414988      PMCID: PMC1346955          DOI: 10.1128/JVI.80.3.1110-1120.2006

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  50 in total

Review 1.  Regulation of the interferon-induced PKR: can viruses cope?

Authors:  M G Katze
Journal:  Trends Microbiol       Date:  1995-02       Impact factor: 17.079

2.  Constitutive activation of Mek1 by mutation of serine phosphorylation sites.

Authors:  W Huang; R L Erikson
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-13       Impact factor: 11.205

3.  Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture.

Authors:  J Chou; E R Kern; R J Whitley; B Roizman
Journal:  Science       Date:  1990-11-30       Impact factor: 47.728

4.  Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma.

Authors:  R Chambers; G Y Gillespie; L Soroceanu; S Andreansky; S Chatterjee; J Chou; B Roizman; R J Whitley
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

5.  Differential response of human cells to deletions and stop codons in the gamma(1)34.5 gene of herpes simplex virus.

Authors:  J Chou; A P Poon; J Johnson; B Roizman
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

6.  Herpes simplex virus 1 gamma(1)34.5 gene function, which blocks the host response to infection, maps in the homologous domain of the genes expressed during growth arrest and DNA damage.

Authors:  J Chou; B Roizman
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-07       Impact factor: 11.205

7.  Evidence that wild-type TP53, and not genes on either chromosome 1 or 11, controls the tumorigenic phenotype of the human fibrosarcoma HT1080.

Authors:  M J Anderson; G Casey; C L Fasching; E J Stanbridge
Journal:  Genes Chromosomes Cancer       Date:  1994-04       Impact factor: 5.006

8.  Interleukin 3 stimulates protein synthesis by regulating double-stranded RNA-dependent protein kinase.

Authors:  T Ito; R Jagus; W S May
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-02       Impact factor: 11.205

9.  The gamma 1(34.5) gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programed cell death in neuronal cells.

Authors:  J Chou; B Roizman
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-15       Impact factor: 11.205

10.  Tumor suppressor function of the interferon-induced double-stranded RNA-activated protein kinase.

Authors:  E F Meurs; J Galabru; G N Barber; M G Katze; A G Hovanessian
Journal:  Proc Natl Acad Sci U S A       Date:  1993-01-01       Impact factor: 11.205

View more
  58 in total

Review 1.  Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates.

Authors:  Guido Wollmann; Koray Ozduman; Anthony N van den Pol
Journal:  Cancer J       Date:  2012 Jan-Feb       Impact factor: 3.360

2.  ONCOLYTIC HERPES SIMPLEX VIRUS 1 (HSV-1) VECTORS: INCREASING TREATMENT EFFICACY AND RANGE THROUGH STRATEGIC VIRUS DESIGN.

Authors:  J Carson; D Haddad; M Bressman; Y Fong
Journal:  Drugs Future       Date:  2010       Impact factor: 0.148

3.  Suppression of extracellular signal-regulated kinase activity in herpes simplex virus 1-infected cells by the Us3 protein kinase.

Authors:  Uyanga Chuluunbaatar; Richard Roller; Ian Mohr
Journal:  J Virol       Date:  2012-05-16       Impact factor: 5.103

4.  Attenuation of herpes simplex virus neurovirulence with picornavirus cis-acting genetic elements.

Authors:  Stephanie A Campbell; Matthew Mulvey; Ian Mohr; Matthias Gromeier
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

5.  Phase ib trial of oncolytic herpes virus G207 shows safety of multiple injections and documents viral replication.

Authors:  Manish K Aghi; E Antonio Chiocca
Journal:  Mol Ther       Date:  2009-01       Impact factor: 11.454

6.  Selective Editing of Herpes Simplex Virus 1 Enables Interferon Induction and Viral Replication That Destroy Malignant Cells.

Authors:  Xing Liu; Bin He
Journal:  J Virol       Date:  2019-01-04       Impact factor: 5.103

Review 7.  Oncolytic virotherapy for pancreatic cancer.

Authors:  Sonia Wennier; Shoudong Li; Grant McFadden
Journal:  Expert Rev Mol Med       Date:  2011-05-18       Impact factor: 5.600

8.  Epithelial-mesenchymal transition enhances response to oncolytic herpesviral therapy through nectin-1.

Authors:  Chun-Hao Chen; Wei-Yi Chen; Shu-Fu Lin; Richard J Wong
Journal:  Hum Gene Ther       Date:  2014-04-02       Impact factor: 5.695

Review 9.  Advances in oncolytic virus therapy for glioma.

Authors:  Amy Haseley; Christopher Alvarez-Breckenridge; Abhik Ray Chaudhury; Balveen Kaur
Journal:  Recent Pat CNS Drug Discov       Date:  2009-01

10.  Prognostic significance of combinations of RNA-dependent protein kinase and EphA2 biomarkers for NSCLC.

Authors:  Chengcheng Guo; Ruping Shao; Arlene M Correa; Carmen Behrens; Faye M Johnson; Maria G Raso; Ludmila Prudkin; Luisa M Solis; Maria I Nunez; Bingliang Fang; Jack A Roth; Ignacio I Wistuba; Stephen G Swisher; Tongyu Lin; Apar Pataer
Journal:  J Thorac Oncol       Date:  2013-03       Impact factor: 15.609

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.